Gevaert P, Omachi TA, Corren J, et al. - Researchers sought to determine omalizumab safety and effectiveness in chronic rhinosinusitis with nasal polyps (CRSwNP), also referred to as nasal polyposis, in phase 3 trials (POLYP 1 and POLYP 2). Adults with CRSwNP with inadequate response to intranasal corticosteroids have been randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. According to findings, patients in POLYP 1 (n = 138) and POLYP 2 (n = 127) showed severe CRSwNP and substantial quality of life impairment evidenced by a mean Nasal Polyp Score higher than 6 and Sino-Nasal Outcome Test-22 score of around 60. Omalizumab significantly improved endoscopic, clinical, and patient-reported results in severe CRSwNP with insufficient intranasal corticosteroid response, and was well tolerated.